EnWave Announces Multiple-Vial Prototype for Pharmaceutical Dehydration and Releases Positive Test Results

Vancouver, B.C., July 13, 2010

EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" or "the Company") has announced that it has begun testing a multiple-vial prototype of the Company's *freeze*REV™ pharmaceutical dehydration technology designed to dry standard industry serum vials containing vaccines, injectable drugs, analytical enzymes, diagnostic reagents, antibodies and other biological materials. The new multiple-vial prototype has a dehydration capacity of up to 100 vials per hour, and has shown significant potential to reduce the time and costs associated with drying vaccines and other biological materials.

"The development of our multiple-vial prototype is a key milestone in the creation of a pharmaceutical dehydration technology capable of meeting the current industry scale of drying tens of thousands of vials per day," said Dr. Tim Durance, Co-CEO of EnWave. "We are building on the success of our single-vial *freeze*REV™ proof-of-concept technology which has shown that we are capable of reducing the effort required to dry vaccines and other biological materials. We have now begun the process of patent protection for this innovation, and initiated a search for a commercial partner who will work with us to scale and automate this technology, and meet industry and the FDA Good Manufacturing Practice standards."

The industry standard dehydration technology, called lyophilization or freeze drying, typically takes 24 to 72 hours to dry biomaterials. *freeze*REV™ has the potential to dry vaccines and other biological materials much faster and cheaper than freeze drying depending on the volume and physical characteristics of the starting material. To date, successful trials of the multiple-vial *freeze*REV™ prototype have been conducted on three products, including a protein solution, a biologically active enzyme, and a live bacteria suspension, demonstrating vast reductions in dehydration time over freeze drying. Furthermore, the recovery of biological activity was equivalent to that obtained through lyophilization, with final moisture content as low as 2.4% which is comparable to the industry standard.

EnWave's proprietary Radiant Energy Vacuum ("REV") technology combines microwave energy with vacuum pressure to produce high-speed dehydration of live or active pharmaceuticals in sterile vials. This process is particularly suitable for creating room temperature stable pharmaceuticals containing live or active materials such as viruses, bacteria and antibodies where an emphasis must be placed on maintaining the maximum possible survival rates until they are delivered to a patient.

EnWave has developed two versions of REV for use in drying live or active pharmaceuticals. *bio*REV™ is a dehydration method for materials which require a gentler drying process without extreme temperature changes or freezing. *freeze*REV™ is a dehydration method for frozen material where low moisture levels in the final product are imperative for long product shelf-life. Both methods dry biomaterials much faster than conventional freeze drying, and both technologies are being designed to require less manufacturing space with higher throughput with the goal of offering significant reductions in processing costs through capital, labour, raw material, energy and time savings.

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is commercializing a new method for dehydrating food and biological materials using Radiant Energy

SUITE 2000 - 1066 WEST HASTINGS ST., VANCOUVER, B.C., CANADA V6E 3X2
Tel (604) 806-6110 Fax (604) 806-6112
TSX Venture Exchange trading symbol: ENW
www.enwave.net

Vacuum technology under its *nutra*REV™, *powder*REV™, *bio*REV™ and *freeze*REV™ brands. REV technology combines microwave energy transfer under vacuum to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include fruit, vegetables, probiotics, enzymes, proteins, food cultures, vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation
Dr. Tim Durance
Chairman and Co-CEO

For further information:

Mr. John McNicol, President & Co-CEO, EnWave Corporation at (604)601-8524
E-mail: john.mcnicol@enwave.net

Jennifer Thompson, V.P. Corporate Development & Investor Relations at (604)603-6549
E-mail: jthompson@enwave.net

Safe Harbour for Forward-Looking Information Statements*: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. There is no guarantee that the Company's REV technology can or will improve processes in the target industry; even if the Company's REV technology can be used as described in this document, there is no guarantee that such use will result in orders for the Company's REV technology. All figures comparing REV technologies to freeze drying or other dehydration technologies are provided as examples of data obtained through the Company's own scientific and testing programs; each product must be tested individually to determine the benefits of using REV.*

SUITE 2000 - 1066 WEST HASTINGS ST., VANCOUVER, B.C., CANADA V6E 3X2
Tel (604) 806-6110 Fax (604) 806-6112
TSX Venture Exchange trading symbol: ENW
www.enwave.net